In population studies, most individuals with mild cognitive impairment (MCI) do not progress to dementia in the near term, but rather remain stable MCI or revert to normal cognition. Here, we characterized MCI subgroups with different outcomes over 5 years. SETTING/PARTICIPANTS: A population-based cohort (N=1603). MEASUREMENTS: Clinical Dementia Rating (CDR); selfreported medical conditions, subjective cognitive concerns, self-rated health, depressive symptoms, blood pressure, medications, blood pressure, APOE genotype, cognitive domain composite scores. DESIGN: We compared 3 MCI subgroups who progressed to dementia (n=86), stabilized at MCI (n=384), or reverted to normal (n=252), to those who remained consistently normal (n=881), defining MCI as CDR = 0.5 and dementia as CDR≥1. Using multinomial logistic regression models adjusted for demographics, we examined the associations of each group with selected baseline characteristics. RESULTS: With the normal group for reference, worse subjective cognitive concerns, functional impairments, selfrated health, and depressive symptoms were associated with being in any MCI group. Taking more prescription medications was associated with being in the stable MCI and reverter groups; diabetes and low diastolic blood pressure
M ild cognitive impairment (MCI) is an intermediate, but
not necessarily transitional, cognitive state between normal cognition and dementia. [1] [2] [3] In specialty clinics, the majority of individuals meeting diagnostic criteria for MCI progress to dementia within a relatively short time. In the community setting, MCI is more heterogeneous; the majority remains stable at the MCI level, a minority progresses to dementia, and another minority reverts to normal. [4] [5] [6] [7] [8] Previous studies have addressed the characteristics of individuals whose MCI progressed to dementia, with features typically resembling the Alzheimer's disease (AD) profile: older age, prominent memory loss, and the apolipoprotein APOE4 genotype. [9] [10] [11] [12] Those whose MCI reverted to normal cognition lacked these characteristics, 10, 12 although in some studies, they too eventually progressed to dementia. 9 The largest group of people with MCI, those who remain stably mildly impaired, have received less attention. 13 Knowing the characteristics associated with likelihood of MCI progression can be helpful to clinicians in treatment planning.
We investigated, at the community level, the 5-year outcomes of MCI: what proportions of people with MCI progressed to dementia, remained at stable MCI, and reverted to normal and, what baseline characteristics distinguished the MCI subgroups from one another and from those who remained consistently normal. Specifically, we compared their distinctive demographic, health, and cognitive characteristics, and their eventual dementia rates and mortality with those of the group with normal cognition.
METHODS
The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) is a cohort participating in a population-based prospective study of cognitive impairment and dementia. It comprised 1,982 individuals recruited from 2006 to 2008 using age-stratified random sampling from the publicly available voter registration list for a group of contiguous small towns in southwestern Pennsylvania. Eligibility criteria included aged 65 and older, noninstitutionalized, lacking severe sensory impairment, and having decisional capacity. Details of sampling, recruitment, and assessment have been reported previously. [14] [15] [16] Participants were reassessed annually. The University of Pittsburgh institutional review board approved all study procedures. All participants provided written informed consent.
Exposure Variables
The assessments included, but were not limited to, demographic characteristics (age, sex), education (high school graduate (HSG), < HSG, >HSG), self-report of diagnoses from a healthcare provider, prescription and nonprescription drug intake, self-rated general health, subjective cognitive concerns, 17 depression symptoms, 18, 19 independence in instrumental activities of daily living (IADLs), lifestyle factors (exercise, smoking, alcohol use), and APOE genotype, as well as a brief, focused, physical and neurological examination. 14, 16, 20 The neuropsychological assessment comprised tests of the cognitive domains of attention and processing speed, memory, executive, language, and visuospatial functions. For each participant, we created a standardized composite score for each domain by first standardizing each individual test score and then calculating the mean of all the standardized scores in that domain. 15 
Classification and Outcome Variables
We rated participants on their everyday independent cognitively driven activity using the Clinical Dementia Rating Scale (CDR); 21 a CDR score of 0 indicates normal cognition, a CDR score of 0.5 indicates MCI, CDR ratings of 1, 2, and 3 indicate mild, moderate, and severe dementia. We used the CDR definition of MCI, which is independent of neuropsychological data, so that we could evaluate baseline cognitive data as predictors of MCI outcomes. We assigned participants CDR ratings at study entry and each annual assessment. Excluding individuals with prevalent dementia (CDR≥1) at study entry, we identified 4 groups: consistently normal (CDR = 0 at up to 10 annual visits), stable MCI (CDR = 0.5 for 5 consecutive visits), reverting or fluctuating MCI (CDR reverts from 0.5 to 0, including any who then return to 0.5, within 5 visits), and progressed to dementia (CDR = 0.5 progresses to CDR ≥1 within 5 visits).
For each participant with MCI, we designated as the "index visit" the first visit at which the CDR score was 0.5. We then measured outcomes over the subsequent 5-year observation period (5 annual visits). Thus, different participants with MCI were followed for different 5-year calendar periods, depending on the dates of their index visits. MCI participants' index visits serve as their baseline; the normal group's baseline visits were their initial (study entry) visits. We compared the baseline characteristics of participants in the 3 MCI subgroups with those of the normal group and with one another. We also compared the reverters who maintained a CDR score of 0 with those who returned to a CDR score of 0.5 (fluctuators). In post hoc analyses, we addressed attrition during the observation period, incident dementia after the observation period, and mortality.
Statistical Methods

Descriptive Statistics
To compare baseline characteristics, overall and between groups, we created indicator variables for self-rated health (poor or fair vs good or excellent), IADL impairment (any vs. none), depressive symptoms (>3 vs ≤3, the 90 th percentile of the MYHAT cohort), subjective cognitive concerns (any vs none), prescription medicines (>3 vs ≤3, a median split), APOE4 genotype (E4 carrier vs noncarrier); history of stroke, transient ischemic attack, heart disease, or diabetes; current smoking, alcohol consumption, and physical exercise, and systolic (>130 vs ≤130 mmHg) and diastolic (>70 vs ≤70 mmHg) blood pressure. We examined cognitive domain composite scores as continuous variables (standardized z scores) and categorized as impaired versus unimpaired at the threshold of 1.5 standard deviations (SDs) below the appropriate mean.
Multivariable Models
We fit multinomial logistic regression models, treating membership in all 4 groups as the outcome variables, with the normal group as reference, to assess the effect of each baseline characteristic on the likelihood of belonging to each group, adjusting for demographic characteristics.
Attrition. We examined the proportions lost to followup in each group during 5 years of follow-up and the average ages at which participants left the study. We fit Cox proportional hazards models with time to dropout as the outcome, adjusting for demographic characteristics. As sensitivity analyses, we repeated the multinomial logistic regression models, excluding those who were lost before completing 5 years of follow-up.
Fluctuation. We compared the reverters who remained at a CDR score of 0 with those who returned to a CDR score of 0.5 during the 5 years (fluctuators).
Subsequent Outcomes. In post hoc analyses, we examined occurrence of incident dementia (CDR ≥ 1) and mortality beyond 5 years.
We used Stata version 15.0 (Stata Corp., College Station, TX) and R 3.4.3 (R Foundation, Vienna, Austria) for all analyses.
Additional methodological details are provided in Supplemental Appendix S1.
RESULTS
Of the 1,982 individuals who met all eligibility criteria at study entry, 1,413 (71.3%) had CDR scores of 0, and 546 (27.6%) had CDR scores of 0.5. We excluded 23 individuals with prevalent dementia, 258 with only initial assessments, 93 with no follow-up assessments after the index visit, and 5 who progressed directly from a CDR score of 0 to a CDR score of 1 or greater without being observed at a 0.5 stage. We report here the data from the remaining 1,603 individuals.
We identified 4 groups: consistently normal (n = 881), reverter or fluctuator (n = 252, 81 of whom fluctuated back to a CDR score of 0.5 during the 5 years), stable MCI (n = 384), progressed to dementia (n = 86).
Participants were followed on average for 6.9 years (normal, 7.0 years; reverters, 8.0 years; stable MCI, 6.0 years; progressors 6.4 years). For all analyses reported in this section, except for the pairwise comparisons, all reported results compare each MCI subgroup with the consistently normal group.
Sample Description (Unadjusted Comparisons)
We found significant overall differences among the 4 groups in several variables in unadjusted analyses of baseline characteristics (Table 1) . We followed up the significant overall differences with pairwise unadjusted comparisons (Supplemental Table S1 ).
In unadjusted analyses of baseline cognitive functioning, all 3 groups of individuals with MCI had significantly lower average composite scores in all domains than those with normal cognition and were significantly less likely to meet operational criteria for cognitive impairment in most domains (Supplemental Table S2 ).
Demographic, Health, and Lifestyle Comparisons Adjusted for Demographic Characteristics (Multivariable Models)
In multinomial logistic regression models, for each independent variable (covariate), we fit a single model for all 3 groups of individuals with MCI simultaneously, adjusting for demographic characteristics. Each relative risk ratio (RRR) indicates the effect size for a given covariate's association with each MCI group compared to the normal group.
For example, in Table 2 , all 3 groups with MCI had significantly more subjective cognitive concerns than those with normal cognition (reverters: RRR=22.6, stable MCI: RRR=16.3, progressors: RRR=12.8; i.e., reverters had the strongest association with subjective concerns, followed by those with stable MCI and progressors). In contrast, IADL impairment was most strongly associated with the progressor group, followed by the stable and reverter groups, all compared to the normal group.
Fair or poor self-rated health and having more than 3 symptoms of depression were approximately equally associated with all MCI groups; number of prescription medications was associated only with the stable MCI and reverter (but not progressor) groups. APOE E4 carrier status was associated with the stable and progressor groups but not the reverter group. Diabetes and diastolic blood pressure (DBP) less than 70 mmHg were associated only with stable MCI. Alcohol use was negatively associated with all 3 MCI groups; smoking and exercise were associated with none.
Cognitive Characteristics of Groups, Adjusted for Demographic Characteristics
In multinomial models (Table 3) , we found associations with lower composite scores in all cognitive domains for all 3 MCI subgroups, with the RRRs indicating progressively stronger effects from reverter through stable to progressor.
Comparing proportions with operationally defined impairments in attention, language, and executive functions, we found increasingly strong effects in the reverter, stable MCI, and progressor groups. In the memory and visuospatial domains, progressors had the strongest effect, followed by those with stable MCI; we found no association in reverters. The executive function domain had the largest effect sizes in all MCI groups.
Attrition
During the 5-year observational period, 29.1% of the group with normal cognition, 29.8% of reverters, 70.8% of those with stable MCI, and 57.0% of progressors were lost to follow-up were; mean age at leaving the study was 80.3 in the group with normal cognition, 85.4 in the reverter group, 86.8 in those with stable MCI, and 87.3 in the progressor group. In Cox proportional hazards models, with time to dropout as the outcome, adjusting for demographic characteristics, the group with stable MCI (hazard ratio (HR)=2.7, 95% confidence interval (CI)=2.3-3.3) and the progressors (HR 1.5, 95% CI=1.1-2.0), but not the reverters, were significantly more likely than those with normal cognition to be lost to follow-up.
In the sensitivity analysis (models excluding those who dropped out before 5 years of follow-up), some power was lost. Effects that were attenuated and became nonsignificant were associations between APOE4 genotype, DBP, smoking, diabetes, and memory impairment and stable MCI; alcohol consumption, language impairment, and attention impairment and reverting; and stroke and transient ischemic attack and progression. We could not assess the effect of executive function impairment because no participants with normal cognition had executive function impairment (data not shown).
Fluctuation
The 81 fluctuators who returned to a CDR score of 0.5 during the 5 years were significantly older (p = .02), reported more subjective cognitive concerns (p = .04), and were more likely to report a history of stroke or transient ischemic attack (p = .03) than the 171 reverters who remained at a CDR score of 0. They had lower scores in the executive (p = .003), memory (p = .01), and visuospatial (p = .003) domain but were more likely to have impairment only in attention (p = .023.
Outcomes Beyond 5 Years
By definition, all progressors developed dementia, and 0% of those with normal cognition developed dementia. Of the 171 reverters who remained at a CDR score of 0 during the 5 years, 19 (11%) subsequently returned to a CDR score of 0.5. Incident dementia was eventually observed in 3 (1.19%) reverters and 15 (3.91%) individuals with stable MCI (Figure 1 ).
Mortality Beyond 5 Years
Progressors had the greatest mortality (44.2%), followed by the stable group (30.5%), reverters (27.4%), and those with normal cognition (21.9%).
DISCUSSION
In a population-based aging cohort followed over at least 5 years, we identified a small subgroup of individuals with MCI who progressed to dementia and larger subgroups that remained stably impaired or reverted to normal. This pattern, typical of community samples, in contrast to clinic samples, 4,5,9,13,22-24 has been attributed to selection factors. 6 More fundamentally, it reflects different distributions of underlying morbidities and risk factors (the heterogeneity of MCI at the population level). We identified shared and distinct baseline features in the 3 MCI groups and those who remained consistently normal.
As in previous studies, 9,24 all 3 MCI groups were older and less well educated than those with normal cognition, with no differences according to sex. The educational gradient across the 4 groups is consistent with lower education being an established risk factor for cognitive decline and dementia. Not unexpectedly, all 3 MCI groups had lower mean composite scores in all cognitive domains and were more likely to report subjective cognitive concerns and IADL impairments than those with normal cognition. Although all MCI groups had lower mean baseline cognitive performance than those with normal cognition, reverters had the highest scores of the MCI groups, followed by the stable group and progressors. Higher proportions of the progressor and stable MCI groups had operationally defined impairment in all domains.
Progressors' characteristics broadly match the typical prodromal AD profile of memory impairment and APOE4 genotype, as in previous community 9, 22 and clinical (4) 3 (4) 5 (4) 5 (5) Baseline for cognitively normal group was study entry (assessment 1). Baseline for MCI groups was the "index visit" at which the participant was first classified as having MCI (Clinical Dementia Rating Scale score = 0.5).
To detect overall group differences, Kruskal-Wallis rank tests were performed for continuous predictors when the assumptions for one-way analysis of variance were not met. Chi-square tests were performed for categorical predictors, and Fisher exact tests were conducted when sample size was small. IQR= interquartile range.
studies. [10] [11] [12] They were also the only group more likely than those with normal cognition to report history of stroke, consistent with evidence that combined neurodegenerative and cerebrovascular disease increases likelihood of dementia. 25, 26 In contrast, reverters resembled those with normal cognition in operationally defined memory and visuospatial impairments, APOE4 genotype, and previous strokes, and had the weakest associations with cognitive and IADL impairments. However, they were the most likely to report at least 1 subjective cognitive concern, although the average number of concerns was fairly similar across MCI groups. The reverters who remained at a CDR score of 0 (unlike the fluctuators, who returned to a CDR score of 0.5) were more likely to have impaired attention, possibly reflecting transient or reversible medically or pharmaceutically derived effects. [27] [28] [29] [30] [31] Reverters were also more likely to take more than 3 prescription drugs, which might contribute to reversible impairments or reflect the presence of underlying reversible morbidities. In effect, these individuals represent potentially reversible MCI.
The stable MCI group was more likely than those with normal cognition to take prescription medications and to have diabetes and low DBP. Stable cardiovascular and metabolic abnormalities might underlie static cognitive impairment. Diabetes is a known risk factor for dementia 32 and MCI. 33 Low DBP could be attributed to factors such as medication effects but is characteristic of heart failure, which could lead to chronic hypoxemia and cerebral hypoperfusion. Low DBP was significantly associated with history of heart failure overall (p = .007) and in the stable MCI group (p < .001). Hypoxemia is implicated in the associations between heart failure and cognitive impairment 34 and between chronic obstructive lung disease and MCI. 35, 36 The stable MCI group was also more likely to have the APOE4 genotype, which is associated not only with AD, but Baseline for cognitively normal group was study entry (assessment 1). Baseline for mild cognitive impairment (MCI) groups was the "index visit" at which the participant was first classified as having MCI (Clinical Dementia Rating Scale score = 0.5). 1 For example, a 1-unit change in the composite attention domain score multiplied the risk of reversion by 0.657, of stable MCI by 0.563, and of progression by 0.375, compared with remaining cognitively normal.
also with hypercholesterolemia and heart disease. 37 However unlike the progressors, those with stable MCI were not more likely than those with normal cognition to report stroke; their cardiovascular disease had not led to cerebrovascular events. They had the highest 5-year attrition rate; in all groups, an unknown proportion of the dropouts might have evidenced dementia had they remained in the study.
With regard to established risk factors or markers of AD, our results validate those of several previous community-based studies. Older age, amnestic MCI, poorer memory performance, worse overall cognitive function, APOE4 genotype, and stroke are consistent predictors of MCI progression to dementia. 9, 11, 22, 24, 38, 39 In neuroimaging studies, medial temporal and global cortical atrophy and rate of volume loss predict progression to dementia. 40 Studies of reverters show the converse. [9] [10] [11] [12] 22, 38 However, we also investigated predictors of nonprogression and the potential roles played by factors reflecting other morbidities and lifestyle factors. The majority of individuals with MCI who remain mildly impaired and the minority who revert to normal may not have underlying progressive neurodegenerative or cerebrovascular processes. Yet nonprogressive impairments also have clinical and public health significance, interfering with everyday functioning, productivity, and quality of life. 41 Our data suggest that these cases of mild impairment may have causes such as diabetes and heart failure. Furthermore, all MCI groups were significantly more likely to report depressive symptoms than those with normal cognition, reflecting the well-documented relationship between depression and cognitive impairment. [42] [43] [44] Here, depressive symptoms did not seem to distinguish between MCI groups, although in another study, they predicted progression to dementia. 45 The cognitive impairments related to these chronic conditions may not be progressive, particularly if the underlying conditions are adequately controlled.
Our study extends the literature in comparing individuals in 3 distinct MCI subgroups with individuals with normal cognition over at least 5 years, and also in examining variables in addition to neuropsychological performance and APOE genotype. Our findings regarding depression symptoms, self-rated health, prescription medications, health history, and DBP appear to be novel. Although our finding of greater IADL impairment and subjective concerns in all MCI groups is as expected, the gradient of effect sizes across MCI groups is informative.
With regard to strengths and limitations, our community-based assessments are less intensive than those in clinical research settings and lack neuroimaging, but our ability to compare people with MCI with cognitively normal individuals from the same population is an advantage over research clinics that rely on highly selected volunteer or referred subjects. Variations in findings-for example, only approximately 1% of the reverters and 4% of those with stable MCI developed incident dementia during the study-can result from varying MCI definitions 9, 22, 24 and statistical approaches. 13 The large size and populationbased nature of our study cohort and 5-year follow-up, longer than others, 46 reinforce external and internal validity. Our study cohort, representing the older population of this study area, is largely of European descent; it should be replicated in other racial and ethnic groups.
MCI subgroups with different 5-year outcomes have some shared and some distinct characteristics. Knowing these relationships can help clinicians with early identification of prognostic subgroups so that the likely progressors and nonprogressors can be targeted for appropriate interventions. All individuals with MCI need not assume that they will progress to dementia, nor should they all be subjected to the same therapeutic strategies. Despite our field's current understandable focus on early detection of progressive dementing diseases, we should not ignore the clinical and public health significance of potentially reversible or stable MCI, which together make up a substantial proportion of mild impairment at the population level.
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